The Regeneron Prescribed drugs firm brand is seen on a constructing on the firm’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Image taken September 17, 2020. REUTERS/Brendan McDermid
Oct 11 (Reuters) – The European Union’s medication regulator mentioned it was evaluating a advertising authorisation for an antibody cocktail developed by Roche (ROG.S) and Regeneron (REGN.O) for the therapy and prevention of COVID-19 in individuals above the age of 12.
The European Medicines Company mentioned on Monday it is going to assess the dangers and advantages of the drug, referred to as Ronapreve, and that it may concern an opinion inside two months. The company has already began a rolling overview of the therapy.
Reporting by Yadarisa Shabong in Bengaluru
Our Requirements: The Thomson Reuters Trust Principles.
